HIPAA-Cratic or HIPAA-Critical: U.S. Privacy Protections Should Be Guaranteed by Covered Entities Working Abroad by Fleming, Grace




HIPAA-Cratic or HIPAA-Critical: U.S. Privacy
Protections Should Be Guaranteed by Covered
Entities Working Abroad
Grace Fleming
Follow this and additional works at: https://scholarship.law.umn.edu/mlr
Part of the Law Commons
This Article is brought to you for free and open access by the University of Minnesota Law School. It has been accepted for inclusion in Minnesota Law
Review collection by an authorized administrator of the Scholarship Repository. For more information, please contact lenzx009@umn.edu.
Recommended Citation
Fleming, Grace, "HIPAA-Cratic or HIPAA-Critical: U.S. Privacy Protections Should Be Guaranteed by Covered Entities Working







HIPAA-Cratic or HIPAA-Critical: U.S. Privacy 
Protections Should Be Guaranteed By Covered 
Entities Working Abroad  
Grace Fleming*
Privacy is a threatened right. Phone calls, emails, and even 
the conversations of heads of state are no longer reliably pri-
vate.
 
1 Health and medical histories contain some of our most 
personal and sensitive information and privacy in this realm is 
of paramount importance. Privacy concerns in health care and 
medical research are intensified by the growth of electronic 
medical records and the rise of the Internet.2 At the touch of a 
button, information can be transferred around the globe. There-
fore, it is no surprise that privacy issues have dominated health 
information discussions in the last half-century.3 The Health 
Insurance Portability and Accountability Act (HIPAA) is de-
signed to address these privacy issues, but because approxi-
mately one-third of U.S.-based clinical trials are now conducted 
outside of the United States,4
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 these protections may not extend 
 1. David E. Sanger & Mark Mazzetti, Allegation of U.S. Spying on Mer-
kel Puts Obama at Crossroads, N.Y. TIMES, Oct. 24, 2013, http://www.nytimes 
.com/2013/10/25/world/europe/allegation-of-us-spying-on-merkel-puts-obama 
-at-crossroads.html.  
 2. See BARRY R. FURROW ET AL., LIABILITY AND QUALITY ISSUES IN 
HEALTH CARE 259 (Thomson West, 6th ed. 2008).  
 3. See id. at 265.  
 4. See Seth W. Glickman et al., Ethical and Scientific Implications of the 
Globalization of Clinical Research, 360 NEW ENG. J. MED. 816, 816 (2009). 
This study used the online registry at ClinicalTrials.gov to look at recruitment 
in industry-sponsored phase three clinical trials as of November 2007 for 
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beyond U.S. borders. The globalization of research has trig-
gered debates about researchers’ ethical obligations concerning 
privacy among large research universities, non-profit organiza-
tions, and other U.S. entities covered by HIPAA.5
In the United States, patients, providers, and researchers 
are increasingly aware of the potential damage caused by a 
breach of privacy.
 As the num-
ber of off-shore clinical trials grows, HIPAA must change to re-
flect this emerging globalized health and biomedical research 
industry. To address the challenges of worldwide threats to 
privacy and the growing importance of health information pri-
vacy to all people, U.S. entities must be required to follow 
HIPAA, both at home and abroad.  
6 Such breaches have included medical rec-
ords improperly discarded in dumpsters,7 patients’ HIV status-
es revealed without patient consent,8 and private health rec-
ords sent to patients’ employers.9
 
twenty of the largest U.S.-based pharmaceutical companies. The study found 
that around one third of the trials (157 of 509) were at that time conducted to-
tally outside the United States and found that a majority of study sites (13,521 
of 24,206) were also outside the United States. The authors wrote that many 
of these trials were being conducted in developing countries.  
 Outside of the United States 
privacy is also a growing issue. Leading up to the May 1, 2011 
capture of Osama Bin Laden in Abbottabad, Pakistan, the Cen-
tral Intelligence Agency (CIA) reportedly implemented a sham 
campaign in which a physician went from house to house gath-
 5. See Carol Bova, Reframing the Influence of the Health Insurance Port-
ability and Accountability Act on Research, 141 CHEST 782, 785 (2012); see al-
so, e.g., International Research, DUKE UNIV. HEALTH SYS. HUM. RES. PROT. 
PROGRAM (Aug. 3, 2011), http://irb.duhs.duke.edu/wysiwyg/downloads/41._ 
International_Research_5-31-2011_revision_8-3-2011.pdf. 
 6. See FURROW ET AL., supra note 2, at 268 (suggesting that concerns 
about privacy in the health industry are a reality and consumers are increas-
ingly vulnerable to breaches of their health information either deliberately or 
accidentally that can come from either an external breach of security or within 
the health care organization itself); Daniel J. Oates, Comment, HIPAA Hypoc-
risy and the Case for Enforcing Federal Privacy Standards Under State Law, 
30 SEATTLE U. L. REV. 745, 745 (2006) (discussing a 1995 privacy catastrophe 
where the daughter of a hospital employee took names and phone numbers 
from medical records of recent emergency room patients and called falsely tell-
ing them they had contracted AIDS).  
 7. See, e.g., Jonathan Rodriguez, Private, Medical Information Left Out 
in a Dumpster, WNCT9 (June 29, 2012), http://www.wnct.com/story/2101 
30221/private-medical-information-left-out-in-a-dumpster.  
 8. See, e.g., Doe v. Medlantic Health Care Gr., Inc., 814 A.2d 939, 942 
(D.C. Cir. 2003). 
 9. See Herman v. Kratche, No. 86697, 2006 WL 3240680, at *1 (Ohio Ct. 
App. 2006).  
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ering DNA under the guise of giving vaccinations.10 This bla-
tant violation of patient privacy, wherein a physician collected 
patient DNA without consent and gave it to the CIA, negatively 
reflects on the entire medical profession—from physicians, to 
researchers, to international humanitarian aid workers. The 
mistrust fostered by such a breach inevitably hinders the aims 
of improved global health, research, and international rela-
tions.11
Congress passed the Health Insurance Portability and Ac-
countability Act (HIPAA) in 1996 to provide standards for the 
use, collection, and disclosure of Protected Health Information 
(PHI).
  
12 In the United States, HIPAA covers all information col-
lected about patients by covered entities that falls under the 
definition of PHI.13 This includes diagnoses, medical records, 
and the patient’s address and phone number.14 Hospitals, phy-
sicians, third party payers, and staff all have a legal duty to 
protect that information.15 The Department of Human Research 
Protections (DHRP) in the U.S. Department of Health and 
Human Services (HHS) has not provided guidance as to wheth-
er HIPAA’s requirements apply to research institutions, drug 
and device companies, or any other U.S.-based research spon-
sor otherwise covered when conducting international clinical 
trials. The Secretary of Health and Human Services Advisory 
Committee on Human Research Protections asked the HHS to 
develop and publish guidelines about HIPAA’s application in 
international research, but as of 2013 this guidance has not 
been produced.16
 
 10. Les F. Roberts & Michael J. VanRooyen, Ensuring Public Health Neu-
trality, 368 NEW ENG. J. MED. 1073, 1073 (2013).  
 Beginning in the 1980s, clinical trials began 
 11. Id. at 1075.  
 12. 45 C.F.R. § 160.103 (2013) (“Health information means any infor-
mation, whether oral or recorded in any form or medium, that: (1) Is created or 
received by a health care provider, health plan, public health authority, em-
ployer, life insurer, school or university, or health care clearinghouse; and 
(2) Relates to the past, present, or future physical or mental health or condi-
tion of an individual; the provision of health care to an individual; or the past, 
present, or future payment for the provision of health care to an individual.”). 
 13. Protected Health Information is information that identifies, or could 
be used to identify an individual and is created by a healthcare provider, 
health plan, employer, or healthcare clearinghouse that relates to that indi-
viduals past, present, or future physical or mental health or payment for the 
provision of healthcare. See id. 
 14. Id.  
 15. See 45 C.F.R. § 164.502(a) (2013).  
 16. See Secretary’s Advisory Committee on Human Research Protections 
Appendix H, OFF. FOR HUM. RES. PROT., U.S. DEP’T OF HEALTH AND HUM. 
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moving abroad because there are substantially fewer regulato-
ry requirements than those applicable in the United States.17 
This movement raises questions about the legal and ethical re-
quirements for clinical researchers and research sponsors that 
are based in the United States but working overseas.18
This Note points out the holes in U.S. privacy laws govern-
ing the obligations of U.S.-covered entities performing research 
abroad. It discusses the debate about HIPAA’s application out-
side the United States and concludes that HIPAA should apply 
to U.S. entities working internationally. Part I provides a brief 
background of HIPAA, including what it does and why it was 
enacted. This background section then discusses current at-
tempts to deal with the gray areas in this law and generally 
explains the notion of standards of care in research. Part II an-
alyzes barriers to implementing HIPAA overseas, discusses 
how these barriers can be mitigated, and employs an ethical 
argument in favor of the United States implementing HIPAA 
abroad. Part III outlines governmental guidance that would 
solve this ambiguity and guarantee privacy protections for all 
human research subjects. It confronts practical barriers to im-
plementation and explains that health information privacy is a 
fundamental human right. HIPAA privacy protections are a 
necessary part of all human subjects research in this increas-
ingly global world and the government must respond to this 
gap by expanding privacy protections.  
  
I.  AN INTRODUCTION TO HIPAA AND THE DEBATE ON 
ITS APPLICATION ABROAD   
HIPAA was the first federal rule to protect the privacy of 
health information and guarantee patient access to that infor-
mation.19 HIPAA recognizes privacy as a fundamental right.20 
However, it is still unclear whether this right must be recog-
nized by U.S. organizations when they work outside of the 
country.21
 
SERVS. (Jan. 6, 2014), http://www.hhs.gov/ohrp/sachrp/appendixh.html. 
 Part A introduces HIPAA’s requirements and the 
 17. PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 650 (Robert C. 
Clark et al. eds., 3d ed. 2007).  
 18. See id. at 818–20; Eve M. Brunts et al., The International Clinical 
Trials Roadmap: Steering Clear of Legal and Practical Roadblocks, J. HEALTH 
& LIFE SCI. L., June 2012, at 1, 1; see also HUTT, supra note 17, at 650.  
 19. See FURROW ET AL., supra note 2, at 264.  
 20. Id.  
 21. See DEP’T OF HEALTH & HUM. SERVS., PROTECTING PERSONAL HEALTH 
INFORMATION IN RESEARCH: UNDERSTANDING THE HIPAA PRIVACY RULE 
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reasons for its enactment. Part B explains that the confusion 
over HIPAA’s application abroad needs to be formally ad-
dressed, and that the confusion stems from its inconsistent ap-
plication in current practice and the history of standards of 
care abuse by U.S. research entities. 
A. HIPAA’S HISTORY AND REQUIREMENTS 
HIPAA was signed into law in 1996 in response to the ex-
panding use of electronic health record technology and the in-
creasing need for industry standardization in using electronic 
health records.22 HIPAA was enacted to address this growing 
use of electronic medical records and confront the many privacy 
and security issues arising from electronic transactions.23
1. HIPAA Basics: Who is Covered and What is Required 
  
HIPAA covers three groups (“covered entities”): (1) health 
plans, both individual and group plans that pay medical care 
costs; (2) health care clearing houses, entities that process in-
formation such as billing companies and community health 
management information systems; and (3) health care provid-
ers such as doctors, nurses, and therapists, and institutional 
providers such as hospitals.24
HIPAA has two parts: the Privacy Rule and the Security 
Rule. The Privacy Rule applies to Protected Health Information 
in all forms—oral, written, and electronic.
  
25 The Privacy Rule 
standardizes how and for what reasons a covered entity can 
disclose a person’s PHI.26 It also outlines penalties for improper 
disclosure and misuse.27 The Security Rule specifically address-
es the issues of electronic PHI.28
 
(2003), [hereinafter DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE 
PRIVACY RULE], available at http://privacyruleandresearch.nih.gov/pdf/ 
HIPAA_booklet_4-14-2003.pdf.  
 It mandates specific protec-
tions that covered entities must have for electronic medical rec-
 22. Young B. Choi et al., Challenges Associated with Privacy in Health 
Care Industry: Implementation of HIPAA and the Security Rules, 30 J. MED. 
SYS. 57, 58 (2006).  
 23. Id.  
 24. DEP’T OF HEALTH & HUM. SERVS., SUMMARY OF THE HIPAA PRIVACY 
RULE, 2–3 (2003), available at http://www.hhs.gov/ocr/privacy/hipaa/ 
understanding/summary/privacysummary.pdf.  
 25. Id.  
 26. Id.  
 27. Id.  
 28. Choi, supra note 22, at 58.  
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ords. These include administrative safeguards and physical 
protections for computer systems and relevant facilities.29 The 
Security Rule requires covered entities to monitor access to 
PHI and lays out specific requirements concerning contracts 
between covered entities and their business associates.30 In ad-
dition, the Security Rule requires that covered entities have 
policies and procedures in place to ensure the health organiza-
tion’s compliance with HIPAA.31
Not all researchers and research institutions in the United 
States have to comply with HIPAA.
 
32 However, a relationship 
with a covered entity folds an otherwise not covered entity un-
der the jurisdiction of HIPAA.33 For example, researchers com-
monly rely on covered entities for funding or as sources of indi-
vidually identifiable health information that is included in 
research databases.34 In other instances, a researcher employed 
by a covered entity may be bound by HIPAA in research en-
deavors undertaken as an employee.35 This coverage varies ac-
cording to the relationship of the researcher or research initia-
tive to a covered entity.36
2. How HIPAA Works and Who Enforces HIPAA 
  
The Office for Civil Rights (OCR) at the U.S. Department 
of Health and Human Services (HHS) enforces HIPAA.37 OCR 
investigates complaints of HIPAA violations, performs audits of 
covered entities, and does outreach and education to encourage 
compliance.38
 
 29. Id. 
 If there is a criminal violation, OCR works with 
 30. Id. A business associate is a person or organization, other than a cov-
ered entity’s workforce, that provides services to a covered entity or performs 
certain functions on behalf of a covered entity and that work involves use or 
disclosure of identifiable health information. Id. This is most often claims pro-
cessing, data analysis, utilization review, or billing. Id.  
 31. Id.  
 32. See DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE PRIVACY 
RULE supra note 21, at 1.  
 33. Id. at 6. For example, a University may be one legal entity that also 
includes an academic medical center. That hospital within the University that 
conducts covered activities, and the relationship it has with the University, 
means that the entire University is subject to HIPAA. Id.  
 34. Id. at 1.  
 35. Id.  
 36. Id.  
 37. See Health Information Privacy, HHS.GOV, http://www.hhs.gov/ocr/ 
privacy/index.html (last visited Apr. 8, 2014).  
 38. See Health Information Privacy: Enforcement Process, HHS.GOV, 
http://www.hhs.gov/ocr/privacy/hipaa/enforcement/ 
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the Department of Justice to enforce HIPAA.39 For the most 
part, OCR works to achieve voluntary compliance through cor-
rective actions and agreements with covered entities.40 Civil 
penalties are only imposed if the violation was willful, and pen-
alties are not imposed if the compliance failure resulted from 
reasonable cause and is rectified within a thirty-day grace peri-
od.41
HIPAA is crucial to protecting patient privacy and contains 
several requirements dedicated to achieving this goal. These 
protections have been largely successful and long-standing.
 
42
B. HIPAA’S APPLICATION ABROAD: CONFUSION IN CURRENT 
PRACTICES AND CURRENT APPROACHES TO STANDARDS OF CARE  
 
The government should respond to the surge in international 
research and ambiguity of HIPAA’s application abroad by ex-
panding HIPAA protections to U.S. covered entities working 
abroad.  
HIPAA’s statutory language and ethical considerations 
governing all human subject research has spurred debate 
among researchers and scholars about whether HIPAA applies 
internationally.43
1. Clues from HIPAA’s Text and Governmental Guidance 
 The government has offered conflicting clues 
on its approach to covered entities working abroad, resulting in 
a patchwork application of privacy laws in the academic re-
search community. One thing, however, is clear: privacy is now 
expected in health settings. 
HHS has not explained, answered, or elaborated on 
HIPAA’s application in international research settings. 
HIPAA’s text and previous HHS guidelines do, however, pro-
vide some clues. HIPAA does not cover foreign national benefi-
ciaries receiving healthcare from the Department of Defense 
(DoD) or by any other federal agency or any agency acting on 
 
process/index.html (last visited Apr. 8, 2014). 
 39. Id.  
 40. See FURROW ET AL., supra note 2, at 282. 
 41. Id.; see 45 C.F.R. § 160.401 (2013) (“Reasonable cause means an act or 
omission in which a covered entity or business associate knew, or by exercising 
reasonable diligence would have known, that the act or omission violated an 
administrative simplification provision, but in which the covered entity or 
business associate did not act with willful neglect.”). 
 42. Choi et al., supra note 22, at 58.  
 43. Bova, supra note 5, at 785.  
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behalf of the DoD or federal agencies.44 This narrow exclusion, 
combined with the broad definition of “individual” in the law 
suggests that foreign nationals are otherwise covered.45 In addi-
tion, HIPAA focuses on covered entities and Protected Health 
Information rather than the nationality of research partici-
pants.46 This has led some researchers and scholars to assume 
that HIPAA does apply in international settings.47 Internation-
al clinical trials can implicate the HIPAA Privacy Rule when 
data is transferred to the United States and the investigator or 
sponsor is a covered entity.48 Therefore, many researchers ar-
gue that HIPAA is not required in international research as 
long as researchers de-identify data or never send the data 
back to the covered entity in the United States.49 In 2004, how-
ever, a member of the Secretary’s Advisory Committee on Hu-
man Research Protection, Mark Barnes, noted that “there is 
nothing in the rule that says it only applies to Americans or 
American residents. It applies to all health information that’s 
identifiable and that is handled by a covered entity, which 
would include [researchers] who are abroad.”50
The text and government statements do not definitively 
answer whether HIPAA applies in international research set-
tings, allowing arguments on both sides. Consequently, it is 
necessary to consider the feasibility of applying HIPAA abroad 
to determine prescribed practices for research entities. These 
concerns ought to influence what kind of guidance the govern-
ment should publish. Researchers currently face uncertainty, 
and a response from the government is necessary.  
  
 
 44. Secretary’s Advisory Committee on Human Research Protections Ap-
pendix H, supra note 16. 
 45. Id. (defining individual as “the person who is the subject of protected 
health information”); see 45 C.F.R. § 160.103 (2013).  
 46. DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE PRIVACY 
RULE, supra note 21, at 1. 
 47. Secretary’s Advisory Committee on Human Research Protections Ap-
pendix H, supra note 16.  
 48. Eve M. Brunts, AHLA Seminar Materials J. Clinical Trials Update 
AHLA-PAPERS P04250708 § VI. C. 1 (Apr. 25, 2007).  
 49. See, e.g., DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra 
note 5, at 1; HIPAA Authorization: International Language, JOHNS HOPKINS 
MED. (Nov. 2010), http://www.hopkinsmedicine.org/institutional_review_ 
board/hipaa_research/hipaa_international_language. 
 50. Thompson To Hear Recommendations to Ease Researchers’ HIPAA 
Concerns, FDA COMPLIANCE EXPERT (July 28, 2004), http://prod-admin1.tmg 
.atex.cniweb.net:8080/preview/www/2.3427/2.3465/1.116184. 
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2. Institutions of Higher Education Approach to HIPAA 
Internationally Exemplifies the Patchwork of Compliance by 
Covered Entities Abroad 
Research programs at universities across the United States 
apply HIPAA abroad in different ways, suggesting that the lack 
of government clarification on this issue has important effects 
on research and, as such, necessitates an immediate response. 
For example, Duke University’s policy acknowledges that 
whether HIPAA applies to international research is an unan-
swered question.51 It notes that once individually identifiable 
information reaches U.S. soil under a covered entity like Duke, 
it becomes subject to HIPAA protections.52 In addition to recog-
nizing the debate over HIPAA’s application abroad, Duke’s pol-
icy also notes that it may be difficult to apply HIPAA in an in-
ternational setting.53 With this in mind, they offer researchers 
the option of requesting that the Institutional Review Board 
(IRB) approve modifications or waivers of HIPAA requirements 
entirely.54
Johns Hopkins takes a similar approach, requiring HIPAA 
protections when international research data is transmitted to 
a covered entity in the United States.
  
55 Likewise, they suggest 
that research teams in foreign countries may alter Johns Hop-
kins’ standard HIPAA privacy language requirements in con-
sent forms as long as they obtain IRB permission.56 IRBs offer 
another check on the ethical practices of researchers and the 
protection of research participants’ rights.57 Yale University 
documents indicate that HIPAA may apply when conducting 
international research if the information gathered is returned 
to the University.58
 
 51. DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note 
 The University recommends that data be 
5, at 
1. 
 52. Id.  
 53. Id.  
 54. Id.  
 55. JOHNS HOPKINS MED., supra note 49. 
 56. Id. This may be to respond to language or educational barriers. 21 
C.F.R. § 56.102 (2013) (“Institutional Review Board (IRB) means any board, 
committee, or other group formally designated by an institution to review, to 
approve the initiation of, and to conduct periodic review of, biomedical re-
search involving human subjects. The primary purpose of such review is to as-
sure the protection of the rights and welfare of the human subjects.”).  
 57. 21 C.F.R. § 56.102 (2013).  
 58. Conducting Research Internationally, YALE UNIV. OFF. OF RES. AD-
MIN., http://researchadministration.yale.edu/ora-services/conducting-research 
-internationally (last visited Apr. 8, 2014). 
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de-identified before the investigator returns to Yale.59
In contrast, the Human Research Protection Program at 
University of California Los Angeles simply notes in its guide-
lines that HIPAA does not apply overseas or in foreign coun-
tries.
  
60 Basic privacy protection measures still apply, but re-
search subjects do not have to sign an authorization to allow 
access to their PHI.61
Duke seems to approach the situation cautiously by ex-
plaining that there is debate about HIPAA’s application abroad 
while noting the importance of privacy.
  
62 Despite requiring re-
searchers to provide equivalent protections to research subjects 
abroad as they would to research subjects in the United States, 
both Duke and Johns Hopkins allow waivers from general 
HIPAA requirements.63 In contrast, UCLA denies that HIPAA 
applies at all.64
3. Standards of Care in Research  
 Universities are hubs of knowledge and are of-
ten leaders in research. These patchwork recommendations 
suggest that HHS guidance is necessary and important to en-
suring the universal, standardized application of human sub-
ject protections. 
Standards of care in research represent the degree of care 
a “reasonable” and “prudent” researcher and research organiza-
tion must exercise.65 These standards are meant to protect hu-
man subjects research participants from abuse. Contemporary 
human subjects protections began in 1947 with the adoption of 
the Nuremberg Code, a set of standards developed by the Nu-
remberg tribunal to judge Nazi experimentation on individuals 
during World War II.66
 
 59. Id. 
 This Code provided the basic principles 
that led to similar recommendations from the World Medical 
 60. HIPAA Frequently Asked Questions, UCLA OFF. OF THE HUM. RES. 
PROT. PROGRAM, http://ora.research.ucla.edu/OHRPP/Pages/HIPAAFAQ.aspx 
(last visited Apr. 8, 2014).  
 61. Id.  
 62. DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note 5, at 
1.  
 63. Id.; JOHNS HOPKINS MED., supra note 49. 
 64. UCLA OFF. OF THE HUM. RES. PROT. PROGRAM, supra note 60. 
 65. Peter Moffett & Gregory Moore, The Standard of Care: Legal History 
and Definitions: The Bad and Good News, 12(1) W.J. EMERGENCY MED. 109, 
109 (2011).  
 66. 45 CFR 46-FAQs, HHS.GOV, http://answers.hhs.gov/ohrp/categories/ 
1562 (last visited Apr. 8, 2014).  
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Association in the 1964 Declaration of Helsinki.67 Following 
several publicized abuses by U.S. researchers, the U.S. gov-
ernment passed the National Research Act in 1974 covering 
human subjects research and created the National Commission 
for the Protection of Human Subjects of Biomedical and Behav-
ioral Research (“Commission”).68 The Commission produced the 
Belmont Report, which provided three ethical guiding princi-
ples for research: respect for persons, beneficence, and justice.69 
The Belmont Report led to the adoption of federal guidelines.70
The “Common Rule” represents the federal policy for the 
protection of human subjects research that has been adopted by 
several federal government agencies.
  
71
When research covered by this policy takes place in foreign countries, 
procedures normally followed in the foreign countries to protect hu-
man subjects may differ from those set forth in this policy. . . In these 
circumstances, if a department or agency head determines that the 
procedures prescribed by the institution afford protections that are at 
least equivalent to those provided in this policy, the department or 
agency head may approve the substitution of the foreign procedures 
in lieu of the procedural requirements provided in this policy.
 It requires that  
72
In recent years, the research community has debated the 
standard of care owed to research subjects in developing coun-
tries.
 
73 The Declaration of Helsinki was revised in 2000 to en-
dorse the view that every trial participant, no matter where the 
trial was located, is entitled to the “worldwide best standard of 
care.”74 This decision suggests that a lower standard of care is 
unethical.75 It violates researcher’s obligations to trial partici-
pants and creates a double standard for the rich and poor.76
 
 67. Id.  
 De-
spite the Declaration’s language, many public, private, nation-
 68. Id.  
 69. THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR 
THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH, THE NAT’L COMM’N FOR 
THE PROT. OF HUM. SUBJECTS OF BIOMEDICAL & BEHAVIORAL RES. (Apr. 18, 
1979), available at http://www.hhs.gov/ohrp/policy/belmont.html.  
 70. Federal Policy for the Protection of Human Subjects (‘Common Rule’), 
HHS.GOV, http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html 
(last visited Apr. 8, 2014). 
 71. Id.  
 72. 45 C.F.R. § 46.101(h) (2013).  
 73. R K Lie et al., The Standard of Care Debate: The Declaration of Hel-
sinki Versus the International Consensus Opinion, 30 J. MED. ETHICS 190, 190 
(2004).  
 74. Id.  
 75. Id.  
 76. Id.  
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al, and international groups have concluded that in some cir-
cumstances, it is ethical to use a different standard of care in 
different countries.77 Standards of care address what is legally 
required, but also encourage the research community to consid-
er what ought to be required. This debate often discusses 
standards in clinical therapies, but not the standards of protec-
tion for research participant information.78
As clinical research moves beyond U.S. borders and guide-
lines remain vague, clinical researchers and research sponsors 
must confront a set of moral concerns around their legal and 
ethical requirements.
 Because privacy 
standards of care abroad is a gray area in U.S. law, it is im-
portant to consider not only whether requiring HIPAA is feasi-
ble, but also whether failing to do so violates research ethics.  
79 Many universities and other covered en-
tities conduct research overseas and admit their confusion in 
whether HIPAA applies in those endeavors.80 In addition, the 
concept of global health has come to the forefront in the last 
decade as influenza and AIDS illustrate the importance of 
global health initiatives and international cooperation and un-
derstanding.81 Finally, medical records are increasingly elec-
tronic. The ease of electronic transfer and collection of data 
heightens privacy concerns.82
Expanding HIPAA’s application faces barriers to imple-
mentation. HIPAA requirements add costs to research.
 As overseas research increases, so 
does the importance of resolving this confusion. A guidance 
document should clarify that HIPAA applies to a covered entity 
working in the United States and abroad, despite roadblocks to 
implementation. Covered entities would then be on notice that 
HIPAA’s protections apply outside the United States, giving all 
research subjects a guaranteed level of protection for personal 
and medical information.  
83 Apply-
ing U.S. federal law in other countries raises issues of extrater-
ritorial application of U.S. law and conflicts of law between 
U.S. privacy laws and privacy laws that exist in the host coun-
try.84
 
 77. Id.  
 Researchers may be concerned about translating an 
 78. See, e.g., id.  
 79. See Bova, supra note 5; Glickman et al., supra note 4.  
 80. See supra Part I.B.2.  
 81. See supra Part I.B.3.  
 82. See FURROW ET AL., supra note 2, at 259.  
 83. See infra Part II.A.2.  
 84. See infra Part II.A.1, II.A.3.  
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American-based privacy theory in countries with different cul-
tural values and languages, the effect of added requirements on 
the progress of research, and practical issues of enforcing 
HIPAA abroad.85
II.  LEGAL AND ETHICAL ANALYSIS OF THE 
FEASIBILITY OF OVERSEAS APPLICATION OF U.S. 
PRIVACY STANDARDS   
 Part II explains these barriers and suggests 
ways to mitigate them. A government decision expanding 
HIPAA’s application will decrease uncertainty and expand an 
improved standard of care concerning privacy to all persons 
participating in research with U.S. covered entities, whether in 
the United States or abroad.  
The Secretary’s Advisory Committee on Human Subjects 
Research asked for further guidance on HIPAA’s application 
abroad.86
A. BARRIERS TO COMPLIANCE WITH HIPAA AND MITIGATING 
THOSE BARRIERS 
 Part A presents potential barriers to expansion 
abroad and how these barriers can be mitigated. Part B dis-
cusses the ethical implications of applying HIPAA overseas, 
concluding that research ethics and standards of care require 
implementation of privacy protections abroad.  
The potential consequences of applying HIPAA abroad 
should be considered and weighed against potential conse-
quences of failing to issue guidance. The barriers to applying 
HIPAA overseas include the extraterritorial application of U.S. 
law, cost, conflicts of law, translation problems, and the poten-
tial for hindering research.  
1. Extraterritorial Application of U.S. Law 
Congress has the power to enforce its laws beyond the ter-
ritorial boundaries of the United States,87
 
 85. See infra Part II.A.4–5.  
 but there is a pre-
sumption that federal legislation applies only within the Unit-
 86. OFF. FOR HUM. RES. PROT., DEP’T OF HEALTH AND HUM. SERVS., supra 
note 16. 
 87. The presumption against extraterritorial application of U.S. law may 
be rebutted if it is clear that the law is intended to apply outside of the United 
States. See Foley Bros. v. Filardo, 336 U.S. 281, 283 (1949) (noting that it is 
not a question whether Congress has the power to extend the Eight Hour Law 
to work performed in foreign countries).  
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ed States.88 This presumption relies on the idea that most legis-
lation is meant to cover domestic rather than foreign issues.89 
Morrison v. National Australia Bank Ltd. suggests that this 
presumption is difficult to circumvent.90
Several considerations may present an exception to the 
presumption when it comes to HIPAA enforcement. If HHS 
produces guidance explicitly indicating that HIPAA applies 
abroad, the presumption can be rebutted.
 This may present a 
significant barrier to the application of HIPAA abroad.  
91 As research and 
other U.S. endeavors become global, the need for extraterritori-
al application of U.S. laws becomes more apparent.92 The pre-
sumption against extraterritorial application can be overcome 
with new guidance from HHS responding to this issue and clar-
ifying that HIPAA must apply abroad.93
 
 88. Morrison v. Nat’l Austl. Bank Ltd., 561 U.S. 247. (2010). 
 This guidance docu-
 89. See Smith v. United States, 507 U.S. 197, 204 (1993). 
 90. Morrison, 130 S. Ct. at 2877 (noting that unless Congress expressly 
writes a law to the contrary, the presumption is that a law is meant to apply 
only within the United States). 
 91. Foley Bros., 336 U.S. at 285 (“The canon of construction which teaches 
that legislation of Congress, unless a contrary intent appears, is meant to ap-
ply only within the territorial jurisdiction of the United States . . . .”). 
 92. See, e.g., Trey Childress, Wal-Mart and the Foreign Corrupt Practices 
Act, CONFLICTOFLAWS.NET (Apr. 24, 2012), http://conflictoflaws.net/2012/wal 
-mart-and-the-foreign-corrupt-practices-act/. 
 93. Agencies often use alternative measures to explain policy preferences 
than the traditional note and comment process as required by the Administra-
tive Procedure Act. These include legal opinions from agency counsel; man-
agement policies; guidance documents; manuals; instruction memoranda; and 
regulatory guidance letters. Sam Kalen, The Transformation of Modern Ad-
ministrative Law: Changing Administrations and Environmental Guidance 
Documents, 35 ECOLOGY L.Q. 657, 659–60 (2008). This provides the agency 
with a flexible way to communicate with regulated parties. Jill E. Family, 
Administrative Law through the Lens of Immigration Law, 64 ADMIN. L. REV. 
565, 566 (2012). Guidance documents are official “‘statement[s] of general ap-
plicability and future effect, other than [regulations]’ that set forth ‘a policy on 
a statutory, regulatory, or technical issue or an interpretation of a statutory or 
regulatory issue.’” Sean Croston, The Petition Is Mightier than the Sword: Re-
discovering an Old Weapon in the Battles over “Regulation Through Guid-
ance,” 63 ADMIN. L. REV. 381, 382 (2011) (quoting Office of Management and 
Budget, Final Bulletin for Agency Good Guidance Practices, 72 Fed. Reg. 3432, 
3434 (Jan. 25, 2007)). Guidance documents may proclaim an agency’s general 
policies and interpretations, but they cannot set forth binding legal require-
ments. They can be practically binding in the effect they have on how the 
agency enforces the policy and the difficulty that ensues for regulated parties 
to challenge the guidance. Id. The enforceability and ability to challenge guid-
ance documents in court is beyond the scope of this Note, but given that this 
would be an interpretation of current HIPAA regulations, it would likely fall 
neatly into what a guidance document is meant to be. Id.  
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ment would interpret the existing HIPAA regulations as apply-
ing overseas.  
2. Cost of HIPAA Compliance 
HIPAA has been called a fiscal bottleneck for biomedical 
research.94 There were many concerns about cost at the outset 
of HIPAA’s implementation.95 HIPAA’s implementation costs 
include training staff on HIPAA compliance and bolstering se-
curity of information both in the physical sense and in the 
technological arena.96 In addition, covered entities incur costs 
in three direct ways: (1) creating new forms for patients regard-
ing privacy practices, (2) appointing or hiring persons to be in 
charge of HIPAA compliance, and (3) needing revisions in busi-
ness associate contracts.97 Indirect costs include time and ener-
gy spent in compliance.98 Finally, there are continual costs to 
maintain HIPAA compliance by training and re-training em-
ployees and maintaining the systems for protecting privacy as 
technology and systems change.99
HIPAA has been a part of U.S. law for over a decade.
  
100 
Startup costs for HIPAA compliance were significant.101 The 
cost of maintaining compliance, however, has been less signifi-
cant than predicted,102
 
 94. Jocelyn Kaiser, Privacy Rule Creates Bottleneck for U.S. Biomedical 
Researchers, 305 SCI. 168, 168 (2004).  
 and the cost of noncompliance can be 
 95. See id.; Peter Kilbridge, The Cost of HIPAA Compliance, 348 NEW 
ENG. J. MED. 1423, 1423 (2003).  
 96. Kilbridge, supra note 95, at 1423. 
 97. Id.  
 98. See Arthur R. Williams et al., HIPAA Costs and Patient Perceptions of 
Privacy Safeguards at Mayo Clinic, 34(1) JOINT COMMISSION J. ON QUALITY & 
PATIENT SAFETY 27, 30 (Jan. 2008).  
 99. Id.  
 100. See 45 C.F.R. § 160.103 (2013).  
 101. See Williams et al., supra note 98, at 30.  
 102. See id.; see also Peter A. Winn, Confidentiality in Cyberspace: The 
HIPAA Privacy Rules and the Common Law, 33 RUTGERS L.J. 617, 679–80 
(2002). 
The most likely explanation of the increase incosts associated with 
the implementation of the HIPAA Privacy Rules appears to be the 
fact that, in recent years, many healthcare providers have invested 
significant resources in increasingly accessible computerized health 
information networks without maintaining appropriate safeguards to 
protect medical information as the accessibility of health information 
increased. As we have seen, traditional standards for confidentiality 
that involved only modest costs when information was stored in 
locked file cabinets, or in main frame computers, now present much 
more difficult and expensive information management problems in 
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high. Actors operating abroad could face monetary costs if HHS 
decides to use the vagueness of the law to enforce HIPAA 
abroad.103
All covered entities in the United States should already be 
in compliance, thus requiring their overseas researchers to 
comply with HIPAA protocols should not significantly increase 
costs.
  
104 Some argue that HIPAA compliance would slow and 
diminish research in the United States, but others see this re-
action as “alarmist.”105 Research in the United States has con-
tinued.106 Much of the infrastructure that allows for continued 
compliance of covered entity researchers in the United States 
could be used when those covered entities operate overseas.107
There are increasing financial consequences for non-
compliance in the United States. In 2009, the maximum penal-
ty was increased from $25,000 to $1.5 million.
 
The infrastructure of compliance is already familiar to most ac-
tors; therefore new cost of compliance barriers are foreseeable 
and will not unfairly stunt research.  
108
 
the context of vast national electronic health networks. Thus, the 
high cost estimates associated with the HIPAA Privacy Rules appear 
to be due simply to the exponential growth in the use of electronic 
health information by the health care industry without a concomitant 
investment in compliance with previously existing duties of confiden-
tiality. 
 A recent case 
Id. 
 103. HITECH Act Enforcement Interim Final Rule, HHS.GOV, http://www 
.hhs.gov/ocr/privacy/hipaa/administrative/enforcementrule/hitechenforcement 
ifr.html (last visited Apr. 8, 2014) (noting a maximum penalty of $1.5 million 
for violations).  
 104. While many were concerned with start-up costs, maintaining compli-
ance has been less strenuous. See Williams et al., supra note 98, at 32 (noting 
that “added into annual operating costs, and spread over the patient census, 
the average privacy cost per patient visit ($0.90) and per patient ($4.00) ap-
pears modest . . . . [M]odest expense (cost) and improved patient information 
are both achievable . . . .”). In addition, HIPAA might lead to cost saving in an 
institution. See Jerry LaMartina, Cost vs. Benefits of HIPAA Is Unclear, but 
Change in Procedures Is a Certainty, KAN. CITY BUS. J., May 19, 2002, 
http://www.bizjournals.com/kansascity/stories/2002/05/20/focus6.html 
(“Standardized electronic transactions could save businesses an estimated $10 
billion to $15 billion during 10 years . . . .”). It could logically follow that main-
taining compliance overseas would not create a significant increase in costs.  
 105. See George J. Annas, HIPAA Regulations—A New Era of Medical-
Record Privacy?, 348 NEW ENG. J. MED. 1486, 1489 (2003).  
 106. See Trends, Charts, and Maps, CLINICALTRIALS.GOV (Nov. 9, 2012), 
http://www.clinicaltrials.gov/ct2/resources/trends (stating that there are cur-
rently 162,059 clinical trials registered on clinicaltrials.gov in the U.S.).  
 107. See supra Part I.B.2. 
 108. Amanda McGrory-Dixon, HHS Toughens HIPAA Violation Penalties, 
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involving a HIPAA violation by a former UCLA employee was 
the first to lead to incarceration.109 In that case, a UCLA re-
searcher was sentenced to jail time for looking at patient rec-
ords he did not have the authorization to view.110
3. Conflicts of Law 
 This signals 
the importance of privacy in health records. While it is unclear 
whether HIPAA applies, if HHS were to interpret the language 
of HIPAA as reaching covered entities abroad, the stakes are 
high for noncompliance. 
Several researchers have concluded that HIPAA must not 
apply internationally because there would be serious conflict of 
law issues.111 These researchers suggest that the foreign laws of 
the country hosting the researchers would trump the applica-
tion of HIPAA.112 For example, the European Union (EU) has 
its own law protecting privacy of personal data.113 This law ap-
plies generally to all EU members, requiring them to protect 
the “right to privacy with respect to the processing of personal 
data” and restrict the flow of information between member 
states.114
Comparing the EU law with HIPAA suggests that conflicts 
of law may be a barrier to applying HIPAA in other countries 
because the EU privacy law has some significant differences 
from the HIPAA privacy rule. For example, the term “personal 
data” is broader than the definition of PHI under HIPAA.
  
115 
The EU Directive defines personal data to include any infor-
mation related to an identified or identifiable natural person.116
 
BENEFITSPRO (Apr. 9, 2013), http://www.benefitspro.com/2013/04/09/hhs 
-toughens-hipaa-violation-penalties; see also HITECH Act Enforcement Inter-
im Final Rule, supra note 
 
In addition, the definition of processing is also broadly defined 
103.  
 109. Pamela Lewis Dolan, HIPAA Violation Leads to Jail Time, 
AMEDNEWS.COM, June 7, 2010, http://www.amednews.com/article/20100607/ 
business/306079969/6/. 
 110. Id.  
 111. Secretary’s Advisory Committee on Human Research Protections Ap-
pendix H, supra note 16.  
 112. Id. 
 113. See, e.g., European Parliament and the Council of the European Un-
ion, Directive 95/46/EC of the European Parliament and of the Council of 24 
October 1995, 1995 O.J. (L 281) 31 (Nov. 23, 1995), available at http://eur 
-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:en:HTML. 
 114. Id. at art. 1.  
 115. Id.  
 116. Id. at art., 2 § a.  
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to mean any operations on personal data including collection, 
recording, storage, use, disclosure, or destruction beyond the 
disclosure and misuse provisions of HIPAA.117 The entity con-
trolling this data is called a “controller” which may at first 
sound like a covered entity.118 However, the EU Directive’s def-
inition of “controller” is not limited to healthcare providers and 
business associates considered by HIPAA.119 Finally, in order 
for a controller to transfer data to a third country, that third 
country must ensure an “adequate level of protection,”120 and 
the EU has determined that the United States does not fulfill 
this criterion.121 To remedy this, the U.S. Department of Com-
merce worked with the European Commission to develop a safe 
harbor provision where U.S. organizations can be deemed to 
have an adequate level of protection.122
Despite the potential for conflicts of law, this does not au-
tomatically preclude HIPAA’s application abroad. Researchers 
may work with their IRB to come up with a solution when 
there is more than one applicable law.
 Differing national pri-
vacy requirements may make ensuring HIPAA compliance 
more complicated when researching outside of the United 
States 
123 In addition, if a re-
search institution or covered entity does a lot of research in a 
region, they may be able to determine what a combination of 
HIPAA with the local privacy laws requires, and use that for 
every study done under the name of that covered entity.124 
HIPAA was designed to minimize conflicts of law among the 
states.125
 
 117. Id. at art. 2, § b. 
 Covered entities or states may require more protec-
 118. See id.  
 119. Id. at art. 2, § d. A controller includes any natural or artificial person, 
public authority, agency, or anything else that processes personal data.  
 120. Id. at art. 25, § 1.  
 121. See Commission Decisions on the Adequacy of the Protection of Person-
al Data in Third Countries, EUROPEAN COMMISSION (2011), http://ec.europa 
.eu/justice/data-protection/document/international-transfers/adequacy/index_ 
en.htm (last visited Apr. 8, 2014).  
 122. Brunts et al., supra note 18, at 20. 
 123. Basic HHS Policy for Protection of Human Subjects, 45 C.F.R. 
§ 46.101 (2013). Institutional Review Boards must approve must approve pro-
posed non-exempt research before beginning research involving human sub-
jects.  
 124. Brunts et al., supra note 18, at 20. 
 125. HIPAA Frequent Questions “How Does the HIPAA Privacy Rule Re-
duce The Potential for Conflict With State Laws?,” HHS.GOV, http://www 
.hhs.gov/hipaafaq/state/401.html (last visited Apr. 8, 2014).  
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tions for individually identifiable health information or create 
greater privacy rights.126 HIPAA is designed to be a floor, mak-
ing it a baseline of protections from which to build upon.127
4. Translation of an American-Based Theory of Privacy  
 If 
the covered entity is working in a country that requires greater 
protections than HIPAA, they will have to follow that country’s 
laws. But if the country has a lower privacy standard or none 
at all, then the covered entity should provide HIPAA’s basic 
level of protections, regardless of the research participant’s citi-
zenship and location of the trial.  
Differing cultural norms around privacy and human rights 
may generate ethical incongruence. Translating HIPAA rights 
and requirements to a culture that may not share the same 
concepts of privacy constitutes a potential barrier to implemen-
tation.128 This has given rise to discourse centering on the valid-
ity of applying an American-based theory of research ethics in a 
different culture,129 and confronting the potential of “medical-
ethical imperialism.”130 The application of an American-based 
theory of privacy overseas through HIPAA may be challenged 
as culturally inappropriate.131
In contrast to the idea that privacy concepts embedded into 
western culture and codified in HIPAA are difficult or non-
translatable in international settings is the issue of practicing 
double standards for U.S.-based research and research 
abroad.
 
132 Translational issues and cultural differences are a 
traditional problem in all parts of international research133
 
 126. Id.  
 but 
they need not hinder research progress. Cultural divides may 
 127. Id.  
 128. See Salla Sariola & Bob Simpson, Theorising the ‘Human Subject’ in 
Biomedical Research: International Clinical Trials and Bioethics Discourses in 
Contemporary Sri Lanka, 73 SOC. SCI. & MED. 515, 516 (2011) (suggesting 
that the philosophies underpinning bioethics are reflective of Anglo-American 
rather than universal values). 
 129. Carel B. IJsselmuiden & Ruth Faden, Research and Informed Consent 
in Africa—Another Look, 326 NEW ENG. J. MED. 830, 830 (1992).  
 130. Id. Medical ethical imperialism involves the imposition of solutions 
culturally appropriate for one society onto another society assuming that those 
solutions represent moral absolutes. See Charles F. Gilks, Ethical Imperial-
ism, 322 NEW ENG. J. MED. 200, 200 (1990).  
 131. IJsselmuiden & Faden, supra note 129, at 830.  
 132. Id.  
 133. S.R. Benatar, Reflections and Recommendations on Research Ethics in 
Developing Countries, 54 SOC. SCI. & MED. 1131, 1135 (2002).  
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be bridged if a researcher invests skill, time and interest in 
breaking down those walls.134 For example, it has been noted 
that in Uganda the western concept of informed consent has 
faced the problems of (i) socioeconomic inequalities between re-
searchers and subjects, which results in subjects feeling they 
have no choice when asked to participate in a research study; 
(ii) colonialism, which instills divides in power and trust be-
tween researchers and subjects; and (iii) erosion of the Ugan-
dan health care system, which left many with a suspicion that 
HIV was brought to Africa by foreigners.135 Researchers should 
be informed of these things before attempting to achieve re-
quired informed consent of research participants. When dis-
cussing privacy, anthropologists indicate that it is typical of Af-
rican culture that individuals perceive themselves as 
extensions of the family.136 They see themselves as an interme-
diaries between ancestors and future generations, not as indi-
vidual persons in their own right who makes decisions only for 
themselves.137 This might mean that privacy, as well as in-
formed consent, cannot be translated to a culture that makes 
decisions as a community. It is important to understand these 
barriers before beginning research. Anthropologic literature in-
volving local health care authorities and the continued assis-
tance of an ethics committee is useful.138
In addition, literature on doctor-patient and scientist-
subject interactions in western countries notes that differences 
in culture and class between the two limits the effectiveness of 
communication, but no one suggests that there be varied 
standards based on such differences.
  
139
5. Increasing Requirements and the Slowing of Research 
 While privacy is not 
necessarily defined the same across all cultures, fears of cul-
tural imperialism may be allayed by making it clear that only 
U.S. firms are expected to adhere to HIPAA guidelines. HIPAA 
was designed as a base of privacy protection able to protect per-
sons regardless of their differences, and moving research 
abroad should not change this standard.  
Complying with HIPAA may require added time and re-
 
 134. Id. 
 135. Id. at 1134.  
 136. See IJsselmuiden & Faden, supra note 129, at 830. 
 137. See id. 
 138. See Benatar, supra note 133, at 1135, 1137.  
 139. See id.  
  
2014] HIPAA-CRATIC OR HIPAA-CRITICAL 2395 
 
sources that would slow the pace of research in clinical trials 
abroad.140 HIPAA would require that resources and time be 
spent explaining privacy rights, training researchers and clini-
cal staff on HIPAA, and setting up safeguards to protect priva-
cy of research subjects.141
The need for data can be immediate. In some cases, it is 
necessary to give research speed a high priority. For example, 
data on HIV transmission, hepatitis B, or multi-drug-resistant 
tuberculosis is critical and time sensitive to those infected and 
to those who may become infected.
  
142 Adding these regulatory 
requirements might hinder the research143
There are many urgent health needs, and many of these 
are rampant in developing countries outside of the United 
States.
 and slow progress in 
the effort to end the global epidemics of these potentially fatal 
illnesses.  
144
The pace at which research findings are actually imple-
mented in the form of new drugs, technologies, and vaccines 
does not support reduced ethical standards.
 The question ought not be whether this research 
needs to be done in haste, but whether that urgency warrants 
reducing ethical standards because of the added time, expense, 
and effort that increasing privacy protections would require.  
145 For example, the 
hepatitis B vaccine was approved for use in the United States 
in the late 1970s.146 Replicating these trials in Africa was im-
portant because there can be different responses in different 
groups.147
 
 140. See IJsselmuiden & Faden, supra note 
 The argument that the urgency of the research find-
ings was so great as to prevent the researchers from complying 
with ethical standards required in the United States is unsup-
ported because even if the vaccine was effective it was unlikely 
129, at 830. 
 141. See supra Part I.A (describing the requirements of HIPAA compli-
ance).  
 142. See, e.g., Press Release, AVAC, Continued Investment in HIV Preven-
tion Research Can Speed Development of New Options To Help End the AIDS 
Epidemic (June 30, 2013), available at http://online.wsj.com/article/PR-CO 
-20130630-900440.html (explaining the urgent need for research in this area).  
 143. Id.  
 144. The Top 10 Global Health Issues To Watch in 2013, 
INTRAHEALTH.ORG, (Jan. 15, 2013), available at http://www.intrahealth.org/ 
page/the-top-10-global-health-issues-to-watch-in-2013.  
 145. See IJsselmuiden & Faden, supra note 129, at 830. 
 146. See Hepatitis B, CTRS. FOR DISEASE CONTROL AND PREVENTION (May 
7, 2012), http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html.  
 147. See id. (discussing how serologic markers of hepatitis B can vary de-
pending on whether the infection is acute or chronic).  
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to be rapidly used and disbursed following this positive find-
ing.148 The inevitable lag between research findings and action 
cripples the argument for decreasing ethical standards in the 
face of urgency for results.149
The debate over whether HIPAA applies to covered entities 
working abroad is exacerbated by the lack of specific guidance 
from HHS.
  
150 In addition, institutions of higher education that 
are often leaders in the research field supply a varied patch-
work of conclusions regarding HIPAA’s implications in interna-
tional research.151
B. ETHICAL ANALYSIS OF PRIVACY STANDARDS  
 Potential consequences of applying HIPAA 
abroad include issues of extraterritorial application of U.S. law, 
added costs, conflicts of law, and translation of privacy to dif-
ferent cultures. While these are not to be ignored, they can be 
mitigated with a flexible approach. Moreover, the consequences 
of not applying HIPAA are grave. 
Costs of not issuing guidance to require compliance with 
HIPAA overseas include both monetary and ethical considera-
tions. This section argues that implementing HIPAA abroad is 
an ethically necessary solution because it would significantly 
add to the propriety of U.S. researchers working abroad, and 
that HIPPA is a baseline of privacy protections that ought to be 
guaranteed by every covered entity.  
1. Past Abuses in Standards of Care and Current Standards of 
Care in Research Highlight the Need for Equity and the 
Importance of Privacy for All Persons 
The AZT trials conducted in the 1990’s in Africa are a 
blemish on U.S. research history in the context of standard of 
care issues. These trials, conducted in Africa, involved research 
on antiretrovirals in preventing transmission of HIV from 
mother to child.152
 
 148. See Hilton Whittle et al., Observational Study of Vaccine Efficacy 14 
Years After the Trial Vaccination in Gambian Children, 325 BMJ 7364 (Sept. 
4, 2002), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC124550/. 
 Although there were established therapies, 
 149. See id.  
 150. See Secretary’s Advisory Committee on Human Research Protections 
Appendix H, supra note 16. 
 151. See DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note 
5; JOHNS HOPKINS MED., supra note 49; UCLA OFF. OF THE HUM. RES. PROT. 
PROGRAM, supra note 60; YALE UNIV. OFF. OF RES. ADMIN., supra note 58. 
 152. See Peter Lurie & Sidney M. Wolfe, Unethical Trials of Interventions 
To Reduce Perinatal Transmission of the Human Immunodeficiency Virus in 
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there was a placebo control arm to the study.153 The placebo 
control arm was defended by researchers, “arguing that the 
subjects are treated at least according to the standard of care in 
these countries, which consists of unproven regimens or no 
treatment at all.”154 Using the host country’s standard of care 
(which may be no standard at all, as in this case), led to outcry 
against the study’s design.155
In August 2011, the families of children who died during a 
meningitis drug trial in Nigeria received their first payments 
following a settlement with the sponsor.
  
156 “[Eleven] children 
died in the trial: five after taking the drug Trovan and six after 
taking an older antibiotic [that was] used for comparison in the 
clinical trial. Others suffered blindness, deafness and brain 
damage.”157  A panel of Nigerian medical experts concluded that 
the study violated international law by testing an unapproved 
drug on children and failing to obtain authorization from the 
Nigerian government for the trial.158 Criticism remains that re-
search moves overseas to avoid U.S. regulatory protections and 
capitalize on less demanding requirements abroad,159 and the 
President’s Commission on Bioethics has stated that there is 
still much room for improvement to protect research subjects.160
The Common Rule states that to gain approval from the 
IRB there must be “adequate provisions to protect the privacy 




Developing Countries, 337 NEW ENG. J. MED. 853 (1997). 
 Pri-
vacy protections must be at least equivalent for those govern-
 153. Id. at 855.  
 154. Id.  
 155. Id. (arguing that any acceptance of the standard of care that does not 
conform to the standard in the sponsoring country leads to a “double standard” 
in research).  
 156. Donald G. McNeil, Jr., Nigerians Receive First Payments for Children 
Who Died in 1996 Meningitis Trial, N.Y. TIMES, Aug. 11, 2011, http://www 
.nytimes.com/2011/08/12/world/africa/12nigeria.html. 
 157. Id.  
 158. Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial in Nigeria, 
WASH. POST, May 7, 2006, http://www.washingtonpost.com/wp-dyn/content/ 
article/2006/05/06/AR2006050601338.html.  
 159. See Stacey B. Lee, Informed Consent: Enforcing Pharmaceutical Com-
panies’ Obligations Abroad, 12(1) HEALTH & HUM. RTS.: INT’L J. 15, 15 (2010), 
available at http://www.hhrjournal.org/2013/08/26/informed-consent-enforcing 
-pharmaceutical-companies-obligations-abroad/. 
 160. See President’s Commission Releases Report on Human Subjects Pro-
tection, BIOETHICS.GOV, http://bioethics.gov/node/559 (last visited Apr. 8, 
2014). This includes greater transparency and accountability. Id.  
 161. 45 C.F.R. § 46.111(a)(7) (2013).  
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ment agencies that have adopted the Common Rule. The Decla-
ration of Helsinki, requires that 
The right of research subjects to safeguard their integrity must al-
ways be respected. Every precaution should be taken to respect the 
privacy of the subject, the confidentiality of the patient’s information 
and to minimize the impact of the study on the subject’s physical and 
mental integrity and on the personality of the subject.162
These documents suggest that privacy is a contemplated 
protection for research subjects both in the United States and 
abroad. Yet, the U.S. government has not taken steps to explic-
itly state that HIPAA is required by all U.S. covered entities 
working overseas and the varied understanding of the nation’s 
research universities illustrates that this question must be ad-
dressed. These examples indicate that the United States has 
faced standards of care issues in the past and has favored ex-
pansion of rights of human subjects. This approach of expand-
ing rights should be furthered in the realm of privacy by adopt-
ing HIPAA’s standards that give practical steps to improve 
privacy protections for all human subjects.  
 
2. Lowered Standards of Care Decrease the Propriety of U.S. 
Researchers and Hinder International Research 
The consequences of reducing ethical standards are great. 
International noncompliance could lead to the loss of patient, 
research subject, or public’s trust that HIPAA aimed to 
achieve.163 Surveys and evidence suggest that patients value 
HIPAA privacy regulations and the rights that come with 
them.164 Potential costs of ethical transgressions in standards of 
care abroad include loss of integrity in research and interna-
tional relations.165
 
 162. World Medical Association Declaration of Helsinki, Bulletin of the 
World Health Org. 374 (2001), available at http://www.who.int/bulletin/ 
archives/79(4)373.pdf. 
 U.S. health work abroad has seen major eth-
ical transgressions that have damaged the reputation of U.S. 
sponsored initiatives. For example, following the false hepatitis 
vaccination scheme to attempt to find Osama Bin Laden, a 
campaign against the polio vaccine and those aid workers who 
 163. See Annas, supra note 105, at 1486 (arguing that the public policy ra-
tional for protection of privacy is that patients will be less likely to disclose de-
tails necessary for proper medical care if they do not trust their physicians to 
keep the information secret, and HIPAA is a way to ensure these principles in 
the electronic age).  
 164. See Williams et al., supra note 98, at 30.  
 165. See Lurie & Wolfe, supra note 152, at 855.  
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administer it has been launched.166 Unarmed volunteers, all 
over Pakistan, Somalia, and Afghanistan are being targeted for 
assassinations and their important vaccines being refused.167 
This same distrust of western medicine and vaccination result-
ed following a research trial of a meningitis drug.168
Standards of care for research subjects can vary, and the 




3. The Potential Costs to Research Participants in Studies 
Using Lower Privacy Standards is Great  
 Privacy is now a part of the accepted standard of care 
and should be recognized as such. Upsetting the public or re-
search community with poor research practices can end a pro-
ject, waste money for the host organization, and damage the in-
tegrity of the research organization as a whole. It is in the best 
interests of researchers and research organizations alike to fol-
low HIPAA standards when overseas.  
Beyond the financial costs and potential standard of care 
conflicts is the human cost of not applying HIPAA overseas. Be-
fore HIPAA was written, the American medical community 
witnessed unauthorized use of medical records for blackmail, 
harassment, job exclusion, and discrediting of persons.170 
HIPAA was enacted in 1996 to address the public’s fears as 
electronic medical records increased the threat of these inva-
sions of privacy.171
 
 166. See Emma Green, Five Global Health Concerns, THE ATLANTIC, Oct. 
5, 2013, http://www.theatlantic.com/events/archive/2013/10/five-global-health 
-concerns/280304/. 
 These fears are just as real in any country. 
Research could implicate a particularly stigmatized subject like 
HIV status, or it may involve private medical histories. Leaving 
people vulnerable to abuse is the human cost of non-
compliance. There should be an obligation to protect infor-
mation collected about medical histories, diagnoses, and other 
PHI so that this information can’t be used to harm participants 
or their families, whether they are U.S. citizens or not.  
 167. Id. 
 168. See McNeil, supra note 156.  
 169. See Part II.B.1.  
 170. The story of Thomas Eagleton is a good example in which his medical 
records were used to discredit his campaign as Vice President. See The Thom-
as Eagleton Affair Haunts Candidates Today, NPR (Aug. 4, 2012), 
http://www.npr.org/2012/08/04/157670201/the-thomas-eagleton-affair-haunts 
-candidates-today; see also supra notes 2–4.  
 171. See Choi et al., supra note 22, at 58. 
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Research subjects often do not have any say in determining 
standards of care. In worst-case scenarios, standards are de-
termined by the financial limitations that these research sub-
jects live with because their government cannot afford the high 
prices set by drug and device companies and medical indus-
try.172 Standards of care should reflect the laws of the entity’s 
home country, not the power asymmetries of the subject coun-
try.173
III.  ISSUING GUIDANCE TO IMPLEMENT HIPAA ABROAD   
 While our laws may not specifically require the applica-
tion of HIPAA abroad, the spirit of the laws we do have, includ-
ing the Common Rule, and the ethical transgressions that led 
to the creation of international standards of care, do require the 
application of HIPAA abroad.  
Universities and other research organizations are unsure 
of the privacy requirements for studies conducted overseas.174 
Standards of care in international research are a constantly 
developing area and privacy is becoming part of that standard, 
ripe for recognition.175
A. WHAT GUIDANCE FROM HHS OUGHT TO LOOK LIKE 
 To require HIPAA compliance interna-
tionally, HHS must issue guidance. Part A explains what guid-
ance from HHS should look like. Part B discusses overcoming 
barriers to implementing HIPAA abroad. Part C argues that 
privacy is a fundamental right, and that basic privacy protec-
tions for research subjects is part of that right.  
HHS must issue guidance clarifying that the scope of 
HIPAA reaches covered entities working overseas. This guid-
ance should state:  
HIPAA privacy protections apply to covered entities work-
ing abroad. All covered entities must comply with the following 
basic privacy protections:  
1. Covered entities must have a set of policies in place for 
compliance with HIPAA.176
2. There must be a system of training of covered entity 
 
 
 172. See Lurie & Wolfe, supra note 152, at 855.  
 173. See Marcia Angell, The Ethics of Clinical Research in the Third World, 
337 N. ENG. J. MED. 847, 848 (1997).  
 174. See supra Part I.B.2.  
 175. See Lie et al., supra note 73, at 190.  
 176. See, e.g., 45 C.F.R. § 164.530(i)(1) (2013) (describing policies and pro-
cedures).  
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staff on compliance and on the importance of privacy.177
3. International patients or research participants should 
receive notice of privacy practices in their own language, so 
they know how their information might be used or disclosed.
 
178
4. Covered entities must have appropriate administrative, 




5. Covered entities should work with their IRB to meet 
these basics and adapt them to their host country and popula-
tion’s needs.  
 
This guidance document would allow flexibility in working 
with the IRB to reach acceptable standards of care and privacy 
policies without sacrificing HIPAA’s requirements and research 
participants’ right to privacy. It would also mean that all cov-
ered entities would clearly know that HIPAA applies abroad 
and that they are required to consider and protect human sub-
jects’ privacy in the United States and abroad. 
The Secretary’s Advisory Committee on Human Research 
Protections has suggested that IRB alterations of HIPAA’s au-
thorization requirements, which involve research subjects giv-
ing permission for the use of their information in the study, 
might be sought.180 This would be a “boiled down” version of the 
elements of authorization.181 The approach from universities in 
response to this debate182 is a good example of potential com-
promise. IRBs and covered entities can work together to deter-
mine how to best protect PHI with the baseline requirements of 
HIPAA as a framework. HIPAA has standards but is also a law 
that allows for flexibility for covered entities to take into ac-
count their costs, size, and level of risk for security breach of 
PHI.183 A covered entity may use any security measures, as long 
as they reasonably and appropriately implement HIPAA 
standards.184
 
 177. See, e.g., id. § 164.530(b)(1) (describing standards for training). 
 This should make it easier for covered entities to 
work with IRB’s to implement HIPAA and protect the privacy 
 178. See, e.g., id. § 164.520 (outlining notice of privacy practices for pro-
tected information). 
 179. See, e.g., id. § 164.530(c)(1) (describing standards for safeguards). 
 180. See Secretary’s Advisory Committee on Human Research Protections 
Appendix H, supra note 16. 
 181. Id.  
 182. See supra Part I.B.2. 
 183. See 45 C.F.R. § 164.306(b).  
 184. Id.  
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of all persons in research or treatment while also taking into 
account the differing needs of researchers and populations.  
Basic HIPAA protections for patient or research partici-
pants’ health histories should be maintained as researchers 
work with their IRB to determine which safeguards are neces-
sary given the nature of the research. HHS guidance should be 
rigid in its principle of privacy protection for research subjects, 
but flexible in building upon HIPAA’s baseline protections, a 
process through which a research entity and IRB may find so-
lutions to the varying issues involved in international research. 
With this clarifying guidance document, covered entities would 
not have to deal with uncertainty as to whether protections ap-
ply abroad and those research subjects with whom they work 
would be guaranteed protection of private personal and medical 
information.185
Although this guidance would simply extend basic privacy 
protections to all persons participating in research with U.S. 
covered entities, the potential barriers to implementation dis-
cussed in Part II.A should be considered. These include extra-
territorial application of U.S. law, costs associated with compli-
ance, conflicts of law, translational issues, and the effect of the 
regulation on the pace of research. In addition, practical con-
cerns including who will enforce the law and how research par-
ticipants will be able to understand the law are important.  
  
B. OVERCOMING BARRIERS TO APPLYING HIPAA OVERSEAS  
As explained in Part II.A, there are several barriers to im-
plementing HIPAA abroad, but with planning and use of cur-
rent HIPAA infrastructure, these barriers are surmountable. 
Extraterritorial application of U.S. law issues can be avoided 
quickly, if HHS issues guidance that HIPAA should apply 
abroad.186 Additional costs to research organizations for imple-
menting HIPAA overseas is a legitimate concern.187 Yet, HIPAA 
has been a part of U.S. law for over a decade,188
 
 185. See Choi et al., supra note 
 and every cov-
ered entity in the United States should already be in compli-
ance. Requiring overseas researchers to follow the same proto-
22, at 58.  
 186. See Foley Bros. v. Filardo, 336 U.S. 281, 283 (1949) (noting that it is 
not a question whether Congress has the power to extend the Eight Hour Law 
to work performed in foreign countries).  
 187. See Kilbridge, supra note 95, at 1423.  
 188. Congress enacted HIPAA in 1996. See The Health Insurance Portabil-
ity and Accountability Act of 1996, Pub. L. 104–91, 110 Stat. 1936.  
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col should not overwhelm those organizations.189
Conflicts of law may arise when applying a U.S. standard 
overseas, but HIPAA is designed to be a floor and a baseline of 
protections from which to build up.
  
190 If a covered entity is 
working in a country that requires more than HIPAA, they will 
have to follow that country’s laws, but if the country has a less 
thorough privacy rule or none at all, then the covered entity 
should provide this basic level of protection, regardless of citi-
zenship. Researchers may work with their IRB to come up with 
the privacy plan to both adequately protect participant privacy 
and comply with all laws.191
Privacy concepts important to a western culture and codi-
fied in HIPAA may not be effective in international settings, 
but practicing double standards for U.S.-based research and re-
search abroad is not the solution.
 
192 Translational issues and 
cultural differences are a traditional problem in all interna-
tional research,193 but if a researcher invests skill, time and in-
terest in understanding those differences there should not be a 
conflict.194 HIPAA was designed as a base of privacy protection 
without regard to differences, and where privacy translation is 
an issue, a researcher may work with their IRB to find a solu-
tion to comply with HIPAA without insulting local culture.195
HIPAA compliance will require added time and resources 
that may slow the pace of research in overseas clinical trials.
  
196 
But reducing ethical standards to potentially increase the pace 
of discovery would not directly lead to faster implementation of 
new drugs, technologies, or vaccines.197
Finally, in addition to the issues with HIPAA application 
discussed above are the practical difficulties in beginning to re-
quire HIPAA compliance overseas. The OCR at HHS may audit 
a covered entity, but they also accept complaints from anyone 
 While reduced pace is a 
risk, it does not warrant a decreased standard of care.  
 
 189. See supra note 104. 
 190. See LaMartina, supra note 104. 
 191. Protection of Human Subjects, 45 C.F.R. § 46.101 (2013). Institutional 
Review Boards must approve must approve proposed non-exempt research be-
fore beginning research involving human subjects. Id. 
 192. See IJsselmuiden & Faden, supra note 129, at 830. 
 193. See Benatar, supra note 133, at 1134–35.  
 194. See id. at 1134–36.  
 195. See id. at 1134. 
 196. See, e.g., IJsselmuiden & Faden, supra note 129, at 831–33 (discussing 
researchers’ obligations when conducting research in developing countries). 
 197. See id. at 830. 
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who feels their privacy rights have been violated.198 There is a 
main office in Washington, D.C., and several smaller investiga-
tor offices throughout the country.199
OCR works to achieve voluntary compliance through cor-
rective actions and agreements with covered entities.
 The current complaint 
process is focused on persons in the United States, and its ex-
pansion may prove difficult. Yet with proper planning these 
practical difficulties can be avoided. 
200 This 
collaboration between covered entities and OCR would likely 
continue. The enforcement process is largely complaint driv-
en.201 As there is no private right of action,202 international re-
search subjects or persons being treated abroad would not be 
able to sue over a HIPAA violation, but they could file com-
plaints with OCR.203 OCR would work towards voluntary com-
pliance with the covered entity to improve their privacy protec-
tions globally.204 Complaints may be submitted electronically or 
in writing, and the OCR offices are adamant that anyone may 
file a complaint, including noncitizens.205 In addition, while it 
may be more difficult for persons outside the United States to 
learn about the OCR process, it is not impossible.206 The infor-
mation is on the internet and available globally,207 and covered 
entities would be required to explain these options as part of 
their privacy policy provided to each research participant be-
fore beginning a study. Resource limits for researchers and re-
search subjects, including reduced access to computers or the 
internet, present a problem to the proper filing of complaints. 
Self-enforcement and voluntary compliance will be even more 
important in the context of research abroad. In addition, the 
IRB and the Ethics Committee should play a role in ensuring 
privacy protections and HIPAA compliance.208
 
 198. See Health Information Privacy: How To File a Complaint, HHS.GOV, 
http://www.hhs.gov/ocr/privacy/hipaa/complaints/index.html (last visited Apr. 
8, 2014). 
 
 199. Id.  
 200. See FURROW ET AL., supra note 2, at 282. 
 201. Id.  
 202. Id.  
 203. See Health Information Privacy: How To File a Complaint, supra note 
198. 
 204. See FURROW ET AL., supra note 2, at 282. 
 205. Id.  
 206. See id.  
 207. Id.  
 208. See Benatar, supra note 133, at 1137 (arguing the importance of ethics 
committees).  
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C. PRIVACY AS A FUNDAMENTAL HUMAN RIGHT 
In the 1890s, future Supreme Court Justice Louis Brandeis 
argued that privacy had become essential to the individual, but 
“modern enterprise and invention have, through invasions up-
on his privacy, subjected him to mental pain and distress, far 
greater than could be inflicted by mere bodily injury.”209 As per-
sonal information becomes more readily available and valua-
ble,210 many are afraid that individual privacy is an unachieva-
ble goal.211 Even though privacy seems to be slipping away, it is 
a fundamental human right.212 It is recognized by the Universal 
Declaration of Human Rights,213 the Declaration of Helsinki,214 
and the International Covenant on Civil and Political Rights.215
 
 209. Samuel D. Warren & Louis D. Brandeis, The Right to Privacy, 4 HARV. 
L. REV. 193, 196 (1890).  
 
Privacy in health is essential to human dignity. The paradox in 
current health care privacy practices is that U.S. researchers 
may either disregard the dignities of our neighbors for scientific 
gain, or risk accusations of cultural imperialism by granting 
them the same rights we expect within our own borders. The 
fluidity of information in the modern age has diminished the 
rigidity of borders and the function of laws that cover only that 
information within them. Privacy may be more difficult to 
achieve, but there remains a moral imperative to enforce priva-
cy in health as a basic human right by guaranteeing protection 
of private information in research in all cases. Expanding 
HIPAA to cover international research would achieve this goal.  
 210. PHI covers any personal information, including identity indicators 
which can be valuable. See 45 C.F.R. § 160.103 (2013). 
 211. See, e.g., Jean-Louis Gassée, NSA Files Show Privacy Does Not Exist, 
THEGUARDIAN.COM (Aug. 5, 2013), http://www.theguardian.com/technology/ 
blog/2013/aug/05/nsa-privacy-surveillance-monday-note.  
 212. See, e.g., Universal Declaration of Human Rights, G.A. Res. 217 (III) 
A, U.N. Doc. A/RES/217(III) (Dec. 10, 1948) ( “No one should be subjected to 
arbitrary interference with his privacy. . . .”); see also Dominic Rushe, UN Ad-
vances Surveillance Resolution Reaffirming ‘Human Right to Privacy,’ 
THEGUARDIAN.COM (Nov. 26, 2013), http://www.theguardian.com/world/ 
2013/nov/26/un-surveillance-resolution-human-right-privacy.  
 213. Universal Declaration of Human Rights, supra note 212. 
 214. World Medical Association Declaration of Helsinki, Bulletin of the 
World Health Org. 374 (2001), available at http://www.who.int/bulletin/ 
archives/79(4)373.pdf. 
 215. International Covenant on Civil and Political Rights, Dec. 16, 1966, S. 
Exec. Rep. 102-23, 999 U.N.T.S. 171. 
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  CONCLUSION   
The expansion of electronic record keeping, the ease of in-
formation sharing, and the rise of clinical trials overseas has 
highlighted the importance of privacy of health information and 
the need for heightened scrutiny of privacy practices of U.S. en-
tities working abroad.216 Privacy has developed into a widely 
recognized basic right.217 Parallel to these increased concerns 
over privacy is the international expansion of clinical research 
by U.S. organizations.218
While HIPAA requires basic privacy protections of health 
information by all covered entities in the United States,
 Regulations to protect this right have 
lagged behind the expansion of operations as globalization of 
healthcare proceeds unabated.  
219 when 
those covered entities leave the United States., HIPAA may no 
longer apply.220 Interpretations vary widely—some believe 
HIPAA does not apply abroad while others think it attaches to 
covered entities regardless of where they work.221 This confu-
sion contributes to an ineffective patchwork of privacy protec-
tions.222
To achieve clarity, the basic protections guaranteed by 
HIPAA should be part of the legal and ethical requirements for 
research or treatment performed by U.S. covered entities both 
in the United States. and internationally. While there are diffi-
culties inherent in expanding HIPAA application overseas, the-
se barriers are not insurmountable and the consequences of 
failing to provide privacy protections can be great. The De-
  
 
 216. FURROW ET AL., supra note 2, at 265.  
 217. Id. at 268–69 (suggesting that privacy is a value on which our society 
is built, but it is also necessary for the effective delivery of care, and a breach 
of health privacy can have implications beyond physical health including loss 
of a job, alienation of family and friends, loss of health insurance, and public 
humiliation).  
 218. See Glickman et al., supra note 4, at 816.  
 219. See Choi et al., supra note 22, at 58. 
 220. See Secretary’s Advisory Committee on Human Research Protections 
Appendix H, supra note 16. 
 221. See id. 
 222. See, e.g., DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra 
note 5 (providing policies for international research to Duke investigators); 
JOHNS HOPKINS MED., supra note 49 (describing John Hopkins’ standard 
practices); UCLA OFF. OF THE HUM. RES. PROT. PROGRAM, supra note 60 (out-
lining HIPAA research); YALE UNIV. OFF. OF RES. ADMIN., supra note 58 
(providing guidance on various rules, regulations, and polices specific to inter-
national research).  
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partment of Health and Human Services must issue guidance 
documents establishing that HIPAA’s requirements extend to 
covered entities whether they are in the United States or 
abroad. This guidance should reflect the basic ideals of HIPAA, 
guaranteeing protection of patient information, including phys-
ical and technical safeguards, as well as organizational policies 
and staff training, while allowing for flexibility to work with 
their IRB to accommodate the needs of research teams and re-
search populations. With this guidance document, covered enti-
ties would not have to deal with uncertainty as to whether pro-
tections apply abroad, and those research subjects they work 
with would be guaranteed a level of protection for personal and 
medical information in an increasingly global world with graver 
consequences for breaches of privacy.  
 
